Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07849348 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria

StatusNot Yet Recruiting
PhaseNot applicable
Started2026-09
View on ClinicalTrials.gov ↗
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate whether starting finerenone together with semaglutide provides an additional reduction in urinary albumin-to-creatinine ratio compared with semaglutide plus matching placebo in adults in China with obesity, albuminuric chronic kidney disease, and without diabetes. Approximately 266 participants will be randomized in a 1:1 ratio. The treatment period will last 24 weeks, followed by a 4-week off-treatment follow-up period.
Trial Details
NCT Number NCT07849348
Lead Sponsor Peking University People's Hospital
Collaborators: Daqing Oil Field Hospital, First Affiliated Hospital Xi'an Jiaotong University, The Second Affiliated Hospital of Qiqihar Medical University, Capital Medical University, Huai'an Fifth People's Hospital, Heilongjiang Provicial Hospital, The First Affiliated Hospital of Henan University of Science and Technology, Shenzhen University General Hospital, Qiqihar First People's Hospital, Zibo Central Hospital, Hebei General Hospital, Suzhou Municipal Hospital, Yan'an University Affiliated Hospital, Tianjin People's Hospital, The First Hospital of Hebei Medical University, Daqing Longnan Hospital, Bayer Healthcare Co., Ltd., Luoyang First People's Hospital, Beijing Pinggu District Hospital
Conditions Obesity; Chronic Kidney Disease; Albuminuria
Enrollment 266 participants
Start Date 2026-09
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-09-30